Compare Enovix Corporation (ENVX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Moderna, Inc. — how do they compare? Enovix Corporation trades at $2.47 (market cap $549.72M), while Moderna, Inc. trades at $221.35 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 143.1× Enovix Corporation's market cap, and Moderna, Inc. is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Moderna, Inc. for 59 Days on average.
| ENVX | MRNA | |
|---|---|---|
Market Cap | $549.72M | $78.65B |
Volume | 6,635,687 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $13.19 | $203.46 |
52-Week Low | $2.50 | $22.36 |
Typical Hold Time | 11 Days | 59 Days |
Enterprise Value | $611.42M | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.485, down 2.55% on the day, reflecting a bearish technical outlook. The company continues to post significant losses, with a net income margin of -473.89% in 2026, though quarterly earnings have consistently beaten expectations. Recent news is dominated by a sudden CEO transition, but the company reaffirmed its strategy and guidance, highlighting progress in its drone and defense battery supply chain.
The outlook is highly speculative. Analyst consensus is bullish with a $10.75 price target, but substantial execution risks and persistent cash burn pose a threat to shareholder value. Investment potential hinges on successful commercialization and achieving profitability, which remains distant.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
